Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the safety, tolerability, pharmacokinetics, and effectiveness of the drug IG3018 in people with high uric acid levels hyperuricemia, including those with and without chronic kidney disease CKD. This phase III clinical trial aims to better understand how IG3018 works in these groups and to explore appropriate dosing. The study is sponsored by Intelligem Therapeutics Australia Pty Ltd and includes participants aged 18 to 75 years. The trial has two parts. Part 1 is a randomized, double-blind, placebo-controlled dose escalation study in participants without CKD, testing increasing doses of IG3018 tablets 0.25 g, 0.5 g, and 1.0 g. Each dose cohort receives a single dose followed by four weeks of twice-daily maintenance dosing. Part 2 is an open-label study in participants with advanced predialysis CKD Stages 3a, 3b, and 4, who receive either 0.5 g or 1.0 g of IG3018 twice daily for four weeks. Participants will attend study visits for blood and urine sample collection to analyze drug levels and kidney function. Safety and efficacy will be assessed through laboratory tests, gout attack monitoring, and uric acid measurements over about 46 days. The study tracks changes in serum uric acid levels, kidney function markers, and drug pharmacokinetics. Participants must provide consent and follow study procedures throughout the treatment and monitoring periods.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the effectiveness of zabalafin hydrogel in people aged 2 years and older who have mild to moderate atopic dermatitis, also known as eczema. This Phase 2b randomized, double-blind study includes two groups one with mild to moderate atopic dermatitis and another with the same condition plus a secondary skin infection. The study aims to compare zabalafin hydrogel to a placebo vehicle to understand its impact on eczema symptoms using a validated global assessment scale. Participants will be randomly assigned in a 21 ratio to receive either zabalafin 9.5% hydrogel or a placebo gel. The study treatment lasts 16 weeks following up to 2 weeks of screening. During treatment, participants will visit the clinic every 2 weeks for the first month and then monthly until the end of the study. The study evaluates not only the effectiveness but also the safety and tolerability of zabalafin compared to the placebo. Throughout the study, participants will undergo assessments including the validated Investigators Global Assessment, Eczema Area and Severity Index, pruritus itching rating, and patient-reported eczema measures. Safety monitoring and evaluation of antibacterial effects in those with skin infections are included. Participants must comply with study procedures, avoid using other topical products on the eczema lesions, and attend scheduled visits over the approximately 16-week treatment period.
Actively Recruiting
Researchers are studying the safety of BHV-1300 as a treatment for adults with Graves Disease. This Phase 1 trial aims to explore how BHV-1300 affects biomarkers related to this condition to better understand its impact. The study is led by Biohaven Therapeutics Ltd. and focuses on monitoring the treatments safety profile over time. Participants will receive BHV-1300, which is given as a subcutaneous injection. This open-label study does not include placebo control or blinding, and all participants receive the same treatment. The treatment period and follow-up extend up to 52 weeks to observe effects and any adverse events. During the study, participants will be closely monitored for serious adverse events, side effects that may lead to stopping treatment, and laboratory abnormalities. Researchers will regularly assess health status and collect data on disease-specific biomarkers. The total duration of participation is approximately one year, ensuring comprehensive safety and effect evaluations.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and immune response of an Acne mRNA vaccine in adults aged 18 to 45 years with moderate to severe acne. This Phase III study is the first to test this vaccine in humans and aims to find the best dose to use in future larger trials. Acne is a common inflammatory skin condition that affects millions worldwide, and current treatments have not changed much over the past 30 years. This study is sponsored by Sanofi Pasteur, a Sanofi Company. The trial includes up to three intramuscular injections of the Acne mRNA vaccine at different dose levels. Participants are divided into four groups two groups receive two injections and two groups receive three injections. Each vaccination group has a matching placebo group for comparison. The Core Study includes Sentinel and Main cohorts for both the two- and three-dose regimens. After completing the Core Study, some participants will enter a long-term follow-up period lasting up to 30 months to assess lasting effects of the vaccine. One group will be invited to join a separate long-term extension study. During the study, participants will be closely monitored for side effects shortly after each injection and for several months thereafter. Researchers will measure changes in the number of acne lesions and immune responses through blood tests. Safety assessments include tracking any adverse events and laboratory test results. Visits will include medical evaluations and questionnaires. The total participation time may extend beyond the Core Study to include long-term follow-up for some participants, lasting up to 38 to 40 months after the first injection.